JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock



Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets I	iabilities and equity
Current assets	53,495,000,000		55,294,000,000		60,979,000,000	
Common stock capital		3,120,000,000		3,120,000,000		3,120,000,000
Fixed assets	114,063,000,000		132,084,000,000		121,039,000,000	
Equity capital of a company		68,774,000,000		76,804,000,000		74,023,000,000
Cash and cash equivalents	21,859,000,000		14,127,000,000		14,487,000,000	
Accrued liabilities		7,149,000,000		6,767,000,000		8,898,000,000
Other assets	-		-		-	
Current liabilities		46,282,000,000		55,802,000,000		45,226,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		52,502,000,000		54,772,000,000		62,769,000,000
Different income		-		-		-
Other liabilities		15,179,000,000		13,443,000,000		15,399,000,000
Total assets	167,558,000,000	167,558,000,000	187,378,000,000	187,378,000,000	182,018,000,000	182,018,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	131,900	152,700	141,700
Equity ratio	41.04%	40.99%	40.67%
Debt-equity ratio	143.64%	143.97%	145.89%

Others

	2023	2022	2021
Tax Expense Rate	11.53%	17.42%	8.33%

JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	85,152,000,000	95,015,000,000	93,758,000,000
Net income	13,326,000,000	17,941,000,000	20,878,000,000
EBIT	14,109,004,800	20,744,400,000	22,062,665,600
Operating income before taxes	15,062,000,000	21,725,000,000	22,776,000,000
Cash Flow	22,791,000,000	21,194,000,000	23,410,000,000
Net interest income	14,000,000	-400,000,000	-755,000,000
Research and development expenses	15,048,000,000	14,752,000,000	14,744,000,000
Income taxes	1,736,000,000	3,784,000,000	1,898,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	605,296	583,406	620,378

Board of Directors

Members of Mana	gement Board	
Jennifer Doudna	Member of Board of Directors	
Mark McClellan	Member of Board of Directors	
Mary Beckerle	Member of Board of Directors	
Nadja West	Member of Board of Directors	
Paula Johnson	Member of Board of Directors	
Anne Mulcahy	Member of Board of Directors	
D. Davis	Member of Board of Directors	
Darius Adamczyk	Member of Board of Directors	
Eugene Woods	Member of Board of Directors	
Hubert Joly	Member of Board of Directors	
Marillyn Hewson	Member of Board of Directors	
Mark Weinberger	Member of Board of Directors	
Joaquin Duato	Chairman of Managing Board	
James Swanson	Member of Executive Committee	
Jennifer Taubert	Member of Executive Committee	
Joseph J. Wolk	Member of Executive Committee	
Kathy Wengel	Member of Executive Committee	
Liz Forminard	Member of Executive Committee	
Peter M. Fasolo	Member of Executive Committee	
Vanessa Broadhurst	Member of Executive Committee	
William N. Hait	Member of Executive Committee	